- Category: Experimental HCV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Gregory Fowler
Hepatitis C and its treatment has been a key focus at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013), taking place this week in Atlanta. Investigators gave an overview of their research and projections about forthcoming approvals of direct-acting antiviral agents at a morning press conference on Monday.
[CROI 2013 "New Frontiers in Hepatitis C Virus Treatment]
Featured investigators include David Thomas from Johns Hopkins (moderator), Eric Lawitz from Alamo Medical Research (AbbVie all-oral regimens), Douglas Dieterich (simeprevir and faldaprevir in interferon-based regimens), and Edward Gane (sofosbuvir/ledipasvir/ribavirin).